Sprint Bioscience AB (SPRINT) - Net Assets
Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has net assets worth Skr106.29 Million SEK (≈ $11.44 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr118.97 Million ≈ $12.80 Million USD) and total liabilities (Skr12.69 Million ≈ $1.37 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Sprint Bioscience AB asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr106.29 Million |
| % of Total Assets | 89.34% |
| Annual Growth Rate | 33.77% |
| 5-Year Change | 69.16% |
| 10-Year Change | 318.24% |
| Growth Volatility | 365.9 |
Sprint Bioscience AB - Net Assets Trend (2011–2025)
This chart illustrates how Sprint Bioscience AB's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Sprint Bioscience AB to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Sprint Bioscience AB (2011–2025)
The table below shows the annual net assets of Sprint Bioscience AB from 2011 to 2025. For live valuation and market cap data, see SPRINT stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr119.18 Million ≈ $12.83 Million |
+1185.34% |
| 2024-12-31 | Skr9.27 Million ≈ $997.82K |
-66.62% |
| 2023-12-31 | Skr27.77 Million ≈ $2.99 Million |
-1.47% |
| 2022-12-31 | Skr28.19 Million ≈ $3.03 Million |
-59.99% |
| 2021-12-31 | Skr70.45 Million ≈ $7.58 Million |
+670.49% |
| 2020-12-31 | Skr9.14 Million ≈ $984.04K |
-17.00% |
| 2019-12-31 | Skr11.02 Million ≈ $1.19 Million |
-70.42% |
| 2018-12-31 | Skr37.24 Million ≈ $4.01 Million |
+32.59% |
| 2017-12-31 | Skr28.09 Million ≈ $3.02 Million |
-1.42% |
| 2016-12-31 | Skr28.49 Million ≈ $3.07 Million |
+491.15% |
| 2015-12-31 | Skr4.82 Million ≈ $518.74K |
-76.28% |
| 2014-12-31 | Skr20.32 Million ≈ $2.19 Million |
+504.23% |
| 2013-12-31 | Skr3.36 Million ≈ $361.91K |
+206.55% |
| 2012-12-31 | Skr1.10 Million ≈ $118.06K |
-45.92% |
| 2011-12-31 | Skr2.03 Million ≈ $218.30K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sprint Bioscience AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17856555000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr7.07 Million | 5.93% |
| Other Components | Skr291.75 Million | 244.81% |
| Total Equity | Skr119.18 Million | 100.00% |
Sprint Bioscience AB Competitors by Market Cap
The table below lists competitors of Sprint Bioscience AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wisher Industrial Co Ltd
TW:1465
|
$41.13 Million |
|
Casing Macron Technology Co Ltd
TWO:3325
|
$41.13 Million |
|
AbL Diagnostics SA
PA:ABLD
|
$41.14 Million |
|
WT Financial Group Ltd
AU:WTL
|
$41.16 Million |
|
Zegona Communications Plc
LSE:ZEG
|
$41.09 Million |
|
Rodex Fasteners
TWO:5015
|
$41.08 Million |
|
RAIZ Invest Ltd
AU:RZI
|
$41.01 Million |
|
Firetail Resources Ltd
AU:FTL
|
$40.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sprint Bioscience AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,272,000 to 119,177,000, a change of 109,905,000 (1185.3%).
- Net income of 91,736,000 contributed positively to equity growth.
- Share repurchases of 18,170,000 reduced equity.
- New share issuances of 23,446,000 increased equity.
- Other factors increased equity by 12,893,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr91.74 Million | +76.97% |
| Share Repurchases | Skr18.17 Million | -15.25% |
| Share Issuances | Skr23.45 Million | +19.67% |
| Other Changes | Skr12.89 Million | +10.82% |
| Total Change | Skr- | 1185.34% |
Book Value vs Market Value Analysis
This analysis compares Sprint Bioscience AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.81x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 12.07x to 2.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | Skr0.30 | Skr3.62 | x |
| 2012-12-31 | Skr0.16 | Skr3.62 | x |
| 2013-12-31 | Skr0.50 | Skr3.62 | x |
| 2014-12-31 | Skr2.32 | Skr3.62 | x |
| 2015-12-31 | Skr0.55 | Skr3.62 | x |
| 2016-12-31 | Skr3.12 | Skr3.62 | x |
| 2017-12-31 | Skr2.86 | Skr3.62 | x |
| 2018-12-31 | Skr3.14 | Skr3.62 | x |
| 2019-12-31 | Skr0.73 | Skr3.62 | x |
| 2020-12-31 | Skr0.44 | Skr3.62 | x |
| 2021-12-31 | Skr2.03 | Skr3.62 | x |
| 2022-12-31 | Skr0.67 | Skr3.62 | x |
| 2023-12-31 | Skr0.40 | Skr3.62 | x |
| 2024-12-31 | Skr0.13 | Skr3.62 | x |
| 2025-12-31 | Skr1.29 | Skr3.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sprint Bioscience AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 76.97%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 54.88%
- • Asset Turnover: 1.22x
- • Equity Multiplier: 1.15x
- Recent ROE (76.97%) is above the historical average (-137.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -67.88% | -58.15% | 0.85x | 1.37x | Skr-1.58 Million |
| 2012 | -323.17% | -223.21% | 0.37x | 3.92x | Skr-3.65 Million |
| 2013 | -130.45% | -185.03% | 0.32x | 2.22x | Skr-4.72 Million |
| 2014 | -56.41% | -248.67% | 0.18x | 1.24x | Skr-13.50 Million |
| 2015 | -321.56% | -200.61% | 0.25x | 6.36x | Skr-15.98 Million |
| 2016 | 15.94% | 12.98% | 0.71x | 1.74x | Skr1.69 Million |
| 2017 | -37.96% | -44.49% | 0.68x | 1.26x | Skr-13.47 Million |
| 2018 | -59.65% | -123.86% | 0.30x | 1.59x | Skr-25.94 Million |
| 2019 | -206.44% | -67.81% | 1.74x | 1.75x | Skr-23.85 Million |
| 2020 | -505.61% | -273.81% | 0.51x | 3.65x | Skr-47.15 Million |
| 2021 | -35.98% | -72.20% | 0.44x | 1.12x | Skr-32.40 Million |
| 2022 | -213.46% | -72493.98% | 0.00x | 1.33x | Skr-62.99 Million |
| 2023 | -1.58% | -0.87% | 0.81x | 2.25x | Skr-3.22 Million |
| 2024 | -197.12% | -27.84% | 1.56x | 4.54x | Skr-19.20 Million |
| 2025 | 76.97% | 54.88% | 1.22x | 1.15x | Skr79.82 Million |
Industry Comparison
This section compares Sprint Bioscience AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $123,979,276
- Average return on equity (ROE) among peers: -30.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sprint Bioscience AB (SPRINT) | Skr106.29 Million | -67.88% | 0.12x | $41.11 Million |
| 2cureX AB (2CUREX) | $74.34 Million | -25.47% | 0.06x | $4.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $77.60 Million | 0.00% | 0.04x | $7.30 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $7.81 Million |
| Active Biotech AB (ACTI) | $405.31 Million | -57.12% | 0.78x | $103.60 Million |
| Alzinova AB (ALZ) | $88.47 Million | -8.57% | 0.04x | $18.28 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $76.43 Million |
| Annexin Pharmaceuticals AB (ANNX) | $46.73 Million | -111.59% | 0.13x | $9.15 Million |
| Alligator Bioscience AB (ATORX) | $3.23 Million | 0.00% | 4.16x | $2.89 Million |
| BioInvent International AB (BINV) | $304.96 Million | 29.40% | 0.13x | $161.11 Million |
| BioArctic AB (publ) (BIOA-B) | $108.28 Million | 3.43% | 0.21x | $2.50 Billion |
About Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a d… Read more